Market closed

Amgen/$AMGN

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Amgen

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Ticker

$AMGN
Sector
Health Care
Trading on
NASDAQ

Industry

Biotechnology
Headquarters
Thousand Oaks, United States

Employees

28,000
Website
www.amgen.com

Amgen Metrics

BasicAdvanced
$171B
42.18
$7.56
0.52
$9.13
2.99%
$171B
0.52
$346.85
$253.30
3.3M
$9.13
1.257
0.843
962.209
1,022.614
117.36%
2.64%
6.40%
67.55%
42.181
5.123
29.13
-4.23
16.475
2.86%
2.99%
18.57%
-39.47%
8.76%
-9.74%
8.53%

What the Analysts think about Amgen

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Amgen stock.

Amgen Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Amgen Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

Amgen News

AllArticlesVideos
Amgen: Riding The MariTide Of Monthly Weight Loss

Amgen: Riding The MariTide Of Monthly Weight Loss

Seeking Alpha·2 days ago
NVO, LLY and AMGN Forecast – Pharma Stocks Look Mixed in Premarket

NVO, LLY and AMGN Forecast – Pharma Stocks Look Mixed in Premarket

FXEmpire·6 days ago
AMGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Amgen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

AMGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Amgen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

GlobeNewsWire·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $AMGN

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

May16
Amgen
Dividend·Ex-dividend
Jun6
Amgen
Dividend·Payment
$2.38
Per share
FAQs

What’s the current market cap for Amgen stock?

Amgen (AMGN) has a market cap of $171B as of March 13, 2025.

What is the P/E ratio for Amgen stock?

The price to earnings (P/E) ratio for Amgen (AMGN) stock is 42.18 as of March 13, 2025.

Does Amgen stock pay dividends?

Yes, the Amgen (AMGN) stock pays dividends to shareholders. As of March 13, 2025, the dividend rate is $9.13 and the yield is 2.99%. Amgen has a payout ratio of 117.36% on a trailing twelve-month basis.

When is the next Amgen dividend payment date?

The next Amgen (AMGN) dividend payment is scheduled for June 06, 2025.

What is the beta indicator for Amgen?

Amgen (AMGN) has a beta rating of 0.52. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.